AIM: To study the expressions of p27 kip1 protein and p27mRNA, the hypermethylation of p27 kip1 and the relation between them in various stages of hepatocarcinogenesis. METHODS: p27 protein and p27mRNA were detected by immunohistochemical staining and in situ hybridization respectively in 68 cases of normal liver, liver cirrhosis, pericancerous cirrhosis and hepatocellular carcinoma (HCC). The hypermethylation of p27 kip1 was detected by methylation-specific PCR (MSP) in 44 cases of normal liver, liver cirrhosis, and HCC. RESULTS: The positive rate of p27 protein was 66.7% (4/6) in normal liver, 60.0% (6/10) in liver cirrhosis, 50.0% (12/24) in pericancerous cirrhosis and 21.4% (6/28) in HCC. There were no statistical differences in normal liver, liver cirrhosis and pericancerous cirrhosis, but the positive rate of p27 protein significantly decreased in HCC compared to that in the other groups (P = 0.006, chi2 = 7.664). The positive rate of p27 kip1 mRNA was 83.3% (5/6) in normal liver, 70.0% (7/10) in liver cirrhosis, 75.0% (18/24) in pericancerous cirrhosis and 25.0% (7/28) in HCC. There were no statistical differences in normal liver, liver cirrhosis and pericancerous cirrhosis, but the positive rate of p27 kip1 mRNA also significantly decreased in HCC compared to that in the other groups (P = 0.000, chi2 = 16.600). In addition, there was a significant correlation between the expression of p27 protein and p27mRNA in the integrated group of normal liver and liver cirrhosis. However, no significant correlation was found between pericancerous cirrhosis and HCC. Using MSP, we found that 1 HCC in 44 cases (including 6 cases of normal liver, 10 cases of liver cirrhosis and 28 cases of HCC) was methylated, whose p27 protein and p27mRNA were negative. CONCLUSION: The reduction or loss of p27 protein and p27mRNA are potentially involved in hepatocarcinogenesis. The hypermethylation of p27 might lead to the loss of p27mRNA transcription.
AIM: To study the expressions of p27 kip1 protein and p27mRNA, the hypermethylation of p27 kip1 and the relation between them in various stages of hepatocarcinogenesis. METHODS:p27 protein and p27mRNA were detected by immunohistochemical staining and in situ hybridization respectively in 68 cases of normal liver, liver cirrhosis, pericancerous cirrhosis and hepatocellular carcinoma (HCC). The hypermethylation of p27 kip1 was detected by methylation-specific PCR (MSP) in 44 cases of normal liver, liver cirrhosis, and HCC. RESULTS: The positive rate of p27 protein was 66.7% (4/6) in normal liver, 60.0% (6/10) in liver cirrhosis, 50.0% (12/24) in pericancerous cirrhosis and 21.4% (6/28) in HCC. There were no statistical differences in normal liver, liver cirrhosis and pericancerous cirrhosis, but the positive rate of p27 protein significantly decreased in HCC compared to that in the other groups (P = 0.006, chi2 = 7.664). The positive rate of p27 kip1 mRNA was 83.3% (5/6) in normal liver, 70.0% (7/10) in liver cirrhosis, 75.0% (18/24) in pericancerous cirrhosis and 25.0% (7/28) in HCC. There were no statistical differences in normal liver, liver cirrhosis and pericancerous cirrhosis, but the positive rate of p27 kip1 mRNA also significantly decreased in HCC compared to that in the other groups (P = 0.000, chi2 = 16.600). In addition, there was a significant correlation between the expression of p27 protein and p27mRNA in the integrated group of normal liver and liver cirrhosis. However, no significant correlation was found between pericancerous cirrhosis and HCC. Using MSP, we found that 1 HCC in 44 cases (including 6 cases of normal liver, 10 cases of liver cirrhosis and 28 cases of HCC) was methylated, whose p27 protein and p27mRNA were negative. CONCLUSION: The reduction or loss of p27 protein and p27mRNA are potentially involved in hepatocarcinogenesis. The hypermethylation of p27 might lead to the loss of p27mRNA transcription.
Authors: M Tsujie; H Yamamoto; N Tomita; Y Sugita; M Ohue; I Sakita; Y Tamaki; M Sekimoto; Y Doki; M Inoue; N Matsuura; T Monden; H Shiozaki; M Monden Journal: Oncology Date: 2000-02 Impact factor: 2.935
Authors: Aristotelis G Anastasiadis; David Calvo-Sanchez; Knut H Franke; Thomas Ebert; Manfred Heydthausen; Wolfgang A Schulz; Martin Burchardt; Claus-Dieter Gerharz Journal: Anticancer Res Date: 2003 Jan-Feb Impact factor: 2.480
Authors: M Nakamura; T Watanabe; U Klangby; C Asker; K Wiman; Y Yonekawa; P Kleihues; H Ohgaki Journal: Brain Pathol Date: 2001-04 Impact factor: 6.508
Authors: Y Ito; N Matsuura; M Sakon; E Miyoshi; K Noda; T Takeda; K Umeshita; H Nagano; S Nakamori; K Dono; M Tsujimoto; M Nakahara; K Nakao; N Taniguchi; M Monden Journal: Hepatology Date: 1999-07 Impact factor: 17.425
Authors: A Tannapfel; D Grund; A Katalinic; D Uhlmann; F Köckerling; U Haugwitz; M Wasner; J Hauss; K Engeland; C Wittekind Journal: Int J Cancer Date: 2000-07-20 Impact factor: 7.396
Authors: Azza E El Bassiouny; Mona M Nosseir; Mona K Zoheiry; Noha A Ameen; Ahmed M Abdel-Hadi; Ibrahim M Ibrahim; Suher Zada; Abdel-Hakeem Saad El-Deen; Nora E El-Bassiouni Journal: World J Hepatol Date: 2010-01-27
Authors: Eckhard Klieser; Christian Mayr; Tobias Kiesslich; Till Wissniowski; Pietro Di Fazio; Daniel Neureiter; Matthias Ocker Journal: Int J Mol Sci Date: 2019-10-23 Impact factor: 5.923